Bios Clinical Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$890,416	122
2024	Research	$873,710	66
2023	Research	$559,360	21
2022	Research	$139,351	8

Breakdown

Who paid Research payments · program years 2022–2025

Gilead Sciences, Inc. $1,662,749 97 payments
ViiV Healthcare Company $515,012 73 payments
GlaxoSmithKline, LLC. $285,075 47 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 2B Single Arm, Repeat Dose Study to Evaluate the Pharmacokinet $335,006 32 payments
A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff $178,448 20 payments
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $143,936 1 payment
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $96,633 1 payment
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $93,100 19 payments
A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff $86,906 22 payments
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $77,714 1 payment
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $72,677 15 payments
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $67,365 1 payment
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection $51,191 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.